fedovapagon + rifampicin

Fedovapagon + rifampicin is a **combination of two pharmaceutical drugs**: fedovapagon, a selective non-peptide vasopressin V2 receptor agonist, and rifampicin, a broad-spectrum antibacterial agent of the rifamycin class. **Fedovapagon** is an oral small molecule developed primarily for the treatment of nocturia by reducing night-time urine production, acting via vasopressin V2 receptor activation in the kidney collecting ducts to increase water reabsorption[2][4][6]. **Rifampicin** is a potent oral or intravenous antibacterial used mainly for tuberculosis and other infections, functioning as a strong inducer of hepatic cytochrome P450 enzymes and hepatic drug-metabolizing enzymes, which can significantly alter the pharmacokinetics of co-administered drugs[5][7]. There are no reports of a fixed-dose formulation or unique clinical application specifically for the combination of fedovapagon and rifampicin. However, the combination may be clinically relevant in the context of potential drug-drug interactions, whereby rifampicin, as a strong CYP450 inducer, could decrease the exposure and effect of fedovapagon if co-administered.